Form 4: PMV Pharmaceuticals Director Charles Baum Acquires 33,500 Stock Options

Charles M. Baum, a Director at PMV Pharmaceuticals, Inc., acquired 33,500 stock options with an exercise price of $0.95, vesting by June 2026 or the next annual meeting.

Summary

• Charles M. Baum, a Director of PMV Pharmaceuticals, Inc. (PMVP), acquired 33,500 stock options.
• The transaction occurred on June 5, 2025, and was reported on a Form 4 filing dated June 9, 2025.
• Each option has an exercise price of $0.95.
• The options were acquired at a price of $0, indicating a grant as part of compensation.
• The underlying securities for these options are 33,500 shares of PMV Pharmaceuticals Common Stock.
• The options are scheduled to vest on the earlier of June 5, 2026, or the date of the Issuer's next annual meeting of stockholders.
• The acquired options have an expiration date of June 5, 2035.
• Following this transaction, Mr. Baum directly beneficially owns 33,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The document reports a routine insider equity grant, which is a standard compensation practice and aligns director interests with shareholders. No negative or unexpected information is present.

Positives

• Director Charles M. Baum's acquisition of 33,500 stock options aligns his financial interests with those of the company's shareholders, as the options gain value only if the stock price increases.
• The grant of stock options is a common and expected component of executive and director compensation, indicating a standard practice in corporate governance.

Risks

• The value of the acquired stock options is dependent on the future performance of PMV Pharmaceuticals' common stock; if the stock price does not rise above the exercise price of $0.95, the options may expire worthless.

Future Outlook

The document indicates that the acquired stock options will vest on the earlier of June 5, 2026, or the date of the Issuer's next annual meeting of stockholders, and will expire on June 5, 2035.

Industry Context

This Form 4 filing details a routine insider transaction, specifically the grant of stock options to a director. Such equity grants are a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of compensation to incentivize long-term performance and align management interests with shareholder value.

Comparison to Industry Standards

• The grant of stock options to directors is a widely adopted compensation practice across the biotechnology and pharmaceutical sectors, including companies like Amgen, Gilead Sciences, and Moderna, which frequently use equity-based incentives to attract and retain talent.
• The vesting schedule, tied to a specific date or the next annual meeting, is typical for director equity awards, similar to practices observed at peer companies.
• The exercise price of $0.95 is specific to PMVP's stock at the time of grant; without the stock's market price on June 5, 2025, a direct comparison of the option's 'in-the-money' or 'at-the-money' status to industry benchmarks is not possible, but the $0 acquisition price for the derivative itself confirms it was a grant.

Related Party Transactions

• The acquisition of stock options by Charles M. Baum, a Director of PMV Pharmaceuticals, Inc., constitutes a related party transaction as it involves an equity grant from the company to an insider as part of his compensation.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align management's incentives with long-term shareholder value creation, as the options' value is tied to the company's stock performance.

Next Steps

• The acquired stock options will vest on the earlier of June 5, 2026, or the date of the Issuer's next annual meeting of stockholders.
• The options will remain exercisable until their expiration date of June 5, 2035.

Key Dates

Recommendation

Keywords

PMV Pharmaceuticals, PMVP, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Biotechnology, Pharmaceuticals